Annual SG&A
$466.32 M
-$357.22 M-43.38%
01 December 2023
Summary:
Sinovac Biotech annual selling, general & administrative expenses is currently $466.32 million, with the most recent change of -$357.22 million (-43.38%) on 01 December 2023. During the last 3 years, it has risen by +$289.79 million (+164.16%). SVA annual SG&A is now -43.38% below its all-time high of $823.54 million, reached on 31 December 2022.SVA Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
N/A
01 June 2024
Summary:
Sinovac Biotech quarterly selling, general & administrative expenses is not available.SVA Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$14.23 B
-$132.30 M-0.92%
01 June 2024
Summary:
Sinovac Biotech TTM selling, general & administrative expenses is currently $14.23 billion, with the most recent change of -$132.30 million (-0.92%) on 01 June 2024. SVA TTM SG&A is now -4.20% below its all-time high of $176.53 million, reached on 31 December 2020.SVA TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SVA Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +164.2% | - | - |
| 5 y5 years | +240.4% | - | +10000.0% |
SVA Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -43.4% | +164.2% | -4.2% | +161.1% | ||
| 5 y | 5 years | -43.4% | +283.9% | -4.2% | >+9999.0% | ||
| alltime | all time | -43.4% | >+9999.0% | -4.2% | >+9999.0% |
Sinovac Biotech Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $466.32 M(-43.4%) | - | - |
| Dec 2022 | $823.54 M(+39.3%) | - | - |
| Dec 2021 | $591.17 M(+234.9%) | - | - |
| Dec 2020 | $176.53 M(+45.3%) | $83.05 M(+75.8%) | $176.53 M(+39.2%) |
| Sept 2020 | - | $47.23 M(+58.5%) | $126.78 M(+11.3%) |
| June 2020 | - | $29.79 M(+80.9%) | $113.95 M(-0.3%) |
| Mar 2020 | - | $16.46 M(-50.6%) | $114.35 M(-5.9%) |
| Dec 2019 | $121.47 M(-11.3%) | $33.30 M(-3.2%) | $121.47 M(-5.7%) |
| Sept 2019 | - | $34.40 M(+14.0%) | $128.87 M(+4.8%) |
| June 2019 | - | $30.19 M(+28.0%) | $122.94 M(-10.4%) |
| Mar 2019 | - | $23.58 M(-42.1%) | $137.25 M(+0.2%) |
| Dec 2018 | $137.00 M(+56.8%) | $40.70 M(+42.9%) | $137.00 M(+42.3%) |
| Sept 2018 | - | $28.48 M(-36.0%) | $96.30 M(+42.0%) |
| June 2018 | - | $44.50 M(+90.7%) | $67.83 M(+190.7%) |
| Mar 2018 | - | $23.33 M(+53.1%) | $23.33 M(-44.4%) |
| Dec 2017 | $87.36 M(+108.1%) | - | - |
| Dec 2016 | $41.98 M(+12.0%) | $15.24 M(+24.1%) | $41.98 M(+9.2%) |
| Sept 2016 | - | $12.28 M(+48.6%) | $38.45 M(+6.4%) |
| June 2016 | - | $8.26 M(+33.3%) | $36.13 M(-2.0%) |
| Mar 2016 | - | $6.20 M(-47.0%) | $36.88 M(-1.6%) |
| Dec 2015 | $37.48 M(+9.2%) | $11.70 M(+17.5%) | $37.48 M(+6.4%) |
| Sept 2015 | - | $9.96 M(+10.5%) | $35.22 M(+4.3%) |
| June 2015 | - | $9.01 M(+32.4%) | $33.78 M(+1.3%) |
| Mar 2015 | - | $6.81 M(-27.9%) | $33.35 M(-2.9%) |
| Dec 2014 | $34.34 M(+2.2%) | $9.44 M(+10.9%) | $34.34 M(+3.5%) |
| Sept 2014 | - | $8.52 M(-0.9%) | $33.17 M(-2.6%) |
| June 2014 | - | $8.59 M(+10.2%) | $34.05 M(-0.6%) |
| Mar 2014 | - | $7.79 M(-5.8%) | $34.25 M(+2.0%) |
| Dec 2013 | $33.61 M(+1.0%) | $8.28 M(-11.9%) | $33.59 M(-15.5%) |
| Sept 2013 | - | $9.39 M(+6.9%) | $39.73 M(+4.1%) |
| June 2013 | - | $8.79 M(+23.1%) | $38.18 M(+5.8%) |
| Mar 2013 | - | $7.14 M(-50.5%) | $36.10 M(+8.5%) |
| Dec 2012 | $33.28 M | $14.41 M(+83.7%) | $33.28 M(+28.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $7.84 M(+17.1%) | $25.94 M(+0.8%) |
| June 2012 | - | $6.70 M(+55.1%) | $25.74 M(+7.2%) |
| Mar 2012 | - | $4.32 M(-39.0%) | $24.02 M(+0.9%) |
| Dec 2011 | $23.81 M(+26.1%) | $7.08 M(-7.4%) | $23.81 M(-1.2%) |
| Sept 2011 | - | $7.64 M(+53.5%) | $24.10 M(+15.5%) |
| June 2011 | - | $4.98 M(+21.2%) | $20.87 M(+5.0%) |
| Mar 2011 | - | $4.11 M(-44.3%) | $19.89 M(+5.3%) |
| Dec 2010 | $18.89 M(+4.0%) | $7.37 M(+67.1%) | $18.89 M(+6.4%) |
| Sept 2010 | - | $4.41 M(+10.5%) | $17.75 M(+5.3%) |
| June 2010 | - | $3.99 M(+28.5%) | $16.86 M(-4.9%) |
| Mar 2010 | - | $3.11 M(-50.2%) | $17.72 M(-2.4%) |
| Dec 2009 | $18.17 M(+4.9%) | $6.24 M(+77.2%) | $18.17 M(+14.7%) |
| Sept 2009 | - | $3.52 M(-27.6%) | $15.83 M(-1.7%) |
| June 2009 | - | $4.86 M(+37.0%) | $16.10 M(-6.8%) |
| Mar 2009 | - | $3.55 M(-9.1%) | $17.28 M(-0.2%) |
| Dec 2008 | $17.31 M(+44.8%) | $3.90 M(+3.0%) | $17.31 M(+9.0%) |
| Sept 2008 | - | $3.79 M(-37.2%) | $15.88 M(-5.8%) |
| June 2008 | - | $6.04 M(+68.8%) | $16.85 M(+27.9%) |
| Mar 2008 | - | $3.58 M(+44.7%) | $13.18 M(+37.3%) |
| Dec 2007 | $11.96 M(+22.6%) | $2.47 M(-48.1%) | $9.60 M(+34.7%) |
| Sept 2007 | - | $4.76 M(+101.7%) | $7.12 M(+201.7%) |
| June 2007 | - | $2.36 M(+18.0%) | $2.36 M(+18.0%) |
| Dec 2006 | $9.75 M(-5.1%) | - | - |
| June 2006 | - | $2.00 M(-21.5%) | $2.00 M(-72.6%) |
| Dec 2005 | $10.28 M(+16.2%) | - | - |
| June 2005 | - | $2.55 M(-1.4%) | $7.29 M(+7.4%) |
| Dec 2004 | $8.84 M(+405.7%) | $2.59 M(+19.8%) | $6.79 M(+61.5%) |
| Sept 2004 | - | $2.16 M(+5.3%) | $4.21 M(+105.3%) |
| June 2004 | - | $2.05 M | $2.05 M |
| Dec 2003 | $1.75 M(+533.8%) | - | - |
| Apr 2002 | $275.90 K(-43.6%) | - | - |
| Apr 2001 | $489.30 K(+40.1%) | - | - |
| Apr 2000 | $349.20 K | - | - |
FAQ
- What is Sinovac Biotech annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Sinovac Biotech?
- What is the all time high quarterly SG&A for Sinovac Biotech?
- What is Sinovac Biotech TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Sinovac Biotech?
What is Sinovac Biotech annual selling, general & administrative expenses?
The current annual SG&A of SVA is $466.32 M
What is the all time high annual SG&A for Sinovac Biotech?
Sinovac Biotech all-time high annual selling, general & administrative expenses is $823.54 M
What is the all time high quarterly SG&A for Sinovac Biotech?
Sinovac Biotech all-time high quarterly selling, general & administrative expenses is $83.05 M
What is Sinovac Biotech TTM selling, general & administrative expenses?
The current TTM SG&A of SVA is $14.23 B
What is the all time high TTM SG&A for Sinovac Biotech?
Sinovac Biotech all-time high TTM selling, general & administrative expenses is $176.53 M